PPPierre-Philippe Piché-Renaud

Pierre-Philippe Piché-Renaud

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pierre-Philippe Piché-Renaud has a total of 167 co-authors. Here are the top co-authors by number of shared publications:

  • Shaun K. Morris

    Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, ON, Canada; Division of Infectious Diseases, The Hospital for Sick Children, Toronto, ON, Canada; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

    13 shared publications
  • Daniel Stephen Farrar

    Centre for Global Child Health, The Hospital for Sick Children, Toronto, Canada

    7 shared publications
  • Costanza Di Chiara

    Division of Pediatric Infectious Diseases, Department for Women’s and Children’s Health, University of Padua, Padua, Italy

    4 shared publications
  • Michelle Science

    Division of Infectious Diseases, The Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G1X8, Canada; Department of Pediatrics, Temerty Faculty of Medicine, University of Toronto, 555 University Avenue, Black Wing Room 1436, Toronto, ON M5G 1X8, Canada

    4 shared publications
  • Upton Allen

    Division of Infectious Diseases and the Transplant and Regenerative Medicine Center, Department of Paediatrics, Hospital for Sick Children University of Toronto Toronto Ontario Canada

    4 shared publications
  • Catherine Ji

    Research and Innovation, North York General Hospital, 4001 Leslie St., Room LE-140, Toronto, ON M2K 1E1, Canada; Department of Family and Community Medicine, Temerty Faculty of Medicine, University of Toronto, 500 University Avenue, 5th Floor, Toronto, Ontario M5G 1V7, Canada; Toronto Western Family Health Team, University Health Network, 440 Bathurst Street, 3(rd) Floor, Toronto, ON M5T 2S6, Canada

    3 shared publications

Latest Publications

  • Open Access

    Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross‐Sectional Study

    by Adria Rose, Rohini R. Datta, Costanza Di Chiara, Pierre‐Philippe Piché‐Renaud, Shaun K. Morris

    Introduction: New RSV prevention products show strong potential, but their success depends on wide acceptance and use. We assessed Ontario pediatricians' knowledge and attitudes about these products before their introduction to highlight opportunities and barriers. Methods: In March−April 2024, Pediatricians Alliance of Ontario newsletter subscribers ( n = 1566) were invited to complete an online survey on RSV knowledge and attitudes. Descriptive analyses with a complete‐case approach assessed responses. Results: Of 117 responses (7% response rate), we retained 104 confirmed as from pediatricians with complete demographic data, including 81% (84/104) general pediatricians and 19% (20/104) subspecialists. Most worked in primary care (40%; 42/104), community hospitals (32%; 33/104), and urban centers (63%; 65/104), and had ≥ 10 years' experience (81%; 83/104). They had high awareness of provincial recommendations (91%; 94/103) and knowledge of severe RSV disease risk factors (Figure 2). While 83% (82/99) always recommended palivizumab to eligible patients, only 34% (34/99) reported that all eligible patients always received it. Over 90% were likely to recommend nirsevimab (91%; 89/98), but 66% (65/98) expected to administer it. Top anticipated barriers included the introduction of a new product (69%; 25/36) and concern for adverse effects (69%; 41/59). The likelihood of recommending a maternal vaccine over nirsevimab was 45% (44/98), while 44% (43/98) were neutral. Conclusion: Ontario pediatricians were knowledgeable and supportive of RSV prevention products. However, they have experienced barriers with palivizumab, and they anticipated barriers with nirsevimab and the maternal RSV vaccine. As other jurisdictions look to implement new RSV prevention products, acknowledging and addressing anticipated barriers may promote acceptance and use.

  • Open Access

    Immunogenicity and Safety of Live Attenuated Varicella Vaccine in Children and Youth With Solid Organ Transplants in Canada: A Canadian Immunization Research Network Study

    by Catherine Burton, Jo Lin Chew, Manish Sadarangani, Tom Blydt-Hansen, Soren Gantt, Shaun K. Morris, Sneha Suresh, Anne Pham-Huy, Anthony Otley, Bruce Tapiero, et al.

    Introduction: Children with solid organ transplants (SOT) face higher risks of severe disease from varicella‐zoster virus (VZV). Although some guidelines recommend live attenuated varicella vaccine (LAVV) for select children post SOT, further real‐world vaccine immunogenicity and safety data are needed. Methods: A prospective observational study was conducted at 4 Canadian centres from 2020 to 2023. Children who were 1–19 years, VZV IgG negative, > 1 year post liver, kidney, or heart transplant, and were receiving LAVV as part of clinical care in accordance with centre‐specific criteria were eligible for inclusion. Measurement of VZV IgG was recommended post‐vaccination with LAVV. Adverse events following immunization (AEFIs) were captured via telephone survey and chart review. Results: Fifty‐six pediatric SOT recipients (51 liver, 3 kidney, and 2 heart) received ≥ 1 dose of LAVV. Serology after the last post‐transplant dose of LAVV was available for 43/56 (77%) participants; 39/43 (91%) seroconverted to positive VZV IgG (12/16 after 1 post‐transplant dose, 26/30 after 2 doses and 1/1 after 3 doses). Among 56 dose 1 recipients, 6 (11%) experienced an AEFI requiring medical attention. Four had rash: 3 with varicella‐like rash (1/3 confirmed vaccine‐strain varicella) and none required antivirals. Two had acute rejection 4–5 weeks after LAVV. Two of 38 (5%) dose 2 recipients had an AEFI requiring medical attention, with one serious AEFI 7 weeks after LAVV that was not deemed vaccine‐related after careful review. Conclusions: LAVV was immunogenic and generally well tolerated in our cohort of patients. Post‐SOT LAVV should be considered for select VZV seronegative children with close follow‐up .


  • Open Access

    Pediatricians’ Attitudes and Knowledge of RSV Immunization Products

    by Costanza Di Chiara, Pierre-Philippe Piché-Renaud, Vera Rigamonti, Anna Cantarutti, Cristina Calvo, Irene Rivero Calle, Antoni Soriano-Arandes, Carlo Giaquinto, Luigi Cantarutti, Daniele Donà, et al.

    Purpose Nirsevimab and the maternal vaccination in pregnancy are newly introduced prevention strategies against respiratory syncytial virus (RSV). This study evaluated pediatricians’ knowledge, attitudes, and barriers to RSV immunization in Italy and Cyprus/Greece, where nirsevimab had not yet been implemented, and in Spain, where it was introduced in 2023/2024. Methods A survey was distributed to pediatricians across Spain, Italy, and Cyprus/Greece in July-August/2024. Occupational characteristics, and knowledge, attitudes and practices toward palivizumab, nirsevimab, and the maternal vaccine were collected. Of 578 respondents (response rate=19.3%), 50% were from Spain, 40% from Italy, and 10% from Cyprus/Greece. As 90% of responses came from Spain and Italy, the main analysis focused on these two countries. Descriptive and univariate analyses (Chi-square or Fisher’s exact tests) were conducted. Results Respondents included pediatricians from community (51.7%), tertiary (30.4%), and primary/secondary care (17.9%) settings. Pediatricians were generally aware of RSV risk factors, without differences across countries. However, 245 (55.9%) and 375 (86.0%) participants reported average-to-low knowledge of nirsevimab and the maternal vaccine, respectively, with differences across countries (p=0.002). Despite limited knowledge, 311 (85.9%) pediatricians were willing to administer nirsevimab, and 319 (92.2%) supported its use for all infants. Nirsevimab administration’s barriers, including unfamiliarity and logistical challenges, were cited by 69 (20.0%) pediatricians. Regarding immunization preferences, 165 (47.4%) pediatricians were very likely to support the maternal vaccine over nirsevimab. Conclusions While pediatricians support RSV immunization, knowledge gaps and logistical barriers may hinder early-stage implementation. Optimizing education on RSV immunization will be crucial to improve uptake and prevention strategies. What’s Known on This Subject There is limited evidence regarding pediatricians’ attitudes and knowledge of nirsevimab and maternal RSV vaccination during pregnancy. What This Study Adds This multi-country survey evaluates pediatricians’ knowledge, attitudes, and barriers to RSV immunization in Italy and Cyprus/Greece, where nirsevimab had not yet been implemented, and in Spain, where it was introduced in 2023/2024.


  • Adverse Events of First-Line Therapy for Pediatric Tuberculosis: A Systematic Review and Meta-Analysis

    by Michael Prodanuk, Sarah L Silverberg, Pierre-Philippe Piché-Renaud, Daniel S Farrar, Jessie Cunningham, Fiona Kritzinger, Valerie Waters, Ray Lam, Ian Kitai

    Background: In 2010, the World Health Organization (WHO) increased the recommended doses of first-line tuberculosis (TB) drugs for children. In this systematic review, we aimed to determine the proportion of children who developed adverse events (AEs) on first-line TB treatment and determine whether a change in toxicity was observed with WHO 2010 dosing. Methods: We searched MEDLINE, Embase, Scopus, Cochrane Central Register of Controlled Trials, WHO Global Index Medicus, and ClinicalTrials.gov for studies that reported AEs for children and adolescents aged ≤19 years with TB disease receiving first-line medications. A meta-analysis of proportions was performed to generate pooled proportions of AEs. The protocol was registered with the International Prospective Register of Systematic Reviews. Results: Of forty studies comprising 5021 participants, 682 (13.6%) participants experienced 712 AEs; 60 (1.2%) participants experienced a change in therapy due to AEs. The proportion of children with any AE was significantly higher with WHO 2010 dosing (26%; 95% confidence interval [CI], 18%–34%) compared with pre-WHO 2010 dosing (8%, 95% CI, 4%–15%), as was the proportion of children who developed severe AEs. There was no significant difference in hepatotoxicity before and after 2010 dosing recommendations; however, significant increases in hepatotoxicity were seen in several subgroups with 2010 dosing. There was substantial heterogeneity between studies; none were at high risk of bias. Conclusions: Higher-dose regimens in children were associated with increased AEs, raising caution for further dose increases and necessitating additional study of treatment tolerability. These findings are limited by publication bias in observational trials.


  • Open Access

    COVID-19 vaccine effectiveness against severe omicron-related outcomes in children aged 5 to 11 years in Ontario: A Canadian immunization research network (CIRN) study

    by Pierre-Philippe Piché-Renaud, Samantha S.M. Drover, Peter C. Austin, Shaun K. Morris, Sarah A. Buchan, Sharifa Nasreen, Kevin L. Schwartz, Mina Tadrous, Nisha Thampi, Sarah E. Wilson, et al.


  • Live‐Attenuated Vaccines in Solid Organ Transplant: Is It Time for a Practice Change?

    by Pierre‐Philippe Piché‐Renaud, Julia Elizabeth Mainwaring Upton

  • Open Access

    COVID-19 vaccine acceptance and uptake among caregivers of children aged 5–11 years in Ontario, Canada: A cross-sectional survey

    by Elahe Karimi-Shahrbabak, Costanza Di Chiara, Daniel S. Farrar, Sarah M. Abu Fadaleh, Joelle Peresin, Brooke Low, David Avelar-Rodriguez, Julia Orkin, Michelle Science, Pierre-Philippe Piché-Renaud, et al.


  • Open Access

    Detection of OXA-181 Carbapenemase in Shigella flexneri

    by Ghulam Dhabaan, Hassan Jamal, Danielle Ouellette, Sarah Alexander, Karen Arane, Aaron Campigotto, Manal Tadros, Pierre-Philippe Piché-Renaud

    We report the detection of OXA-181 carbapenemase in an azithromycin-resistant Shigella spp. bacteria in an immunocompromised patient. The emergence of OXA-181 in Shigella spp. bacteria raises concerns about the global dissemination of carbapenem resistance in Enterobacterales and its implications for the treatment of infections caused by Shigella bacteria.


  • Open Access

    COVID-19 vaccine equity: a retrospective population-based cohort study examining primary series and first booster coverage among persons with a history of immigration and other residents of Ontario, Canada

    by Susitha Wanigaratne, Hong Lu, Sima Gandhi, Janavi Shetty, Therese A. Stukel, Pierre-Philippe Piché-Renaud, Julia Brandenberger, Samiya Abdi, Astrid Guttmann

    Introduction: Immigrants were disproportionately impacted by COVID-19 and experience unique vaccination barriers. In Canada (37 million people), 23% of the population is foreign-born. Immigrants constitute 60% of the country’s racialized (non-white) population and over half of immigrants reside in Ontario, the country’s most populous province. Ontario had several strategies aimed at improving vaccine equity including geographic targeting of vaccine supply and clinics, as well as numerous community-led efforts. Our objectives were to (1) compare primary series vaccine coverage after it was widely available, and first booster coverage 6 months after its availability, between immigrants and other Ontario residents and (2) identify subgroups experiencing low coverage.Materials and methods: Using linked immigration and health administrative data, we conducted a retrospective population-based cohort study including all community-dwelling adults in Ontario, Canada as of January 1, 2021. We compared primary series (two-dose) vaccine coverage by September 2021, and first booster (three-dose) coverage by March 2022 among immigrants and other Ontarians, and across sociodemographic and immigration characteristics. We used multivariable log-binomial regression to estimate adjusted risk ratios (aRR).Results: Of 11,844,221 adults, 22% were immigrants. By September 2021, 72.6% of immigrants received two doses (vs. 76.4%, other Ontarians) and by March 2022 46.1% received three doses (vs. 58.2%). Across characteristics, two-dose coverage was similar or slightly lower, while three-dose coverage was much lower, among immigrants compared to other Ontarians. Across neighborhood SARS-CoV-2 risk deciles, differences in two-dose coverage were smaller in higher risk deciles and larger in the lower risk deciles; with larger differences across all deciles for three-dose coverage. Compared to other Ontarians, immigrants from Central Africa had the lowest two-dose (aRR = 0.60 [95% CI 0.58–0.61]) and three-dose coverage (aRR = 0.36 [95% CI 0.34–0.37]) followed by Eastern Europeans and Caribbeans, while Southeast Asians were more likely to receive both doses. Compared to economic immigrants, resettled refugees and successful asylum-claimants had the lowest three-dose coverage (aRR = 0.68 [95% CI 0.68–0.68] and aRR = 0.78 [95% CI 0.77–0.78], respectively).Conclusion: Two dose coverage was more equitable than 3. Differences by immigrant region of birth were substantial. Community-engaged approaches should be re-invigorated to close gaps and promote the bivalent booster.


  • Prevention and treatment of traumatic brain injury-related delirium: a systematic review

    by Yu Qing Huang, Sophie Weiss, Priti Gros, Edwin Wong, Pierre-Philippe Piché, Manav V. Vyas, Alan Ka Ho Tam, Jennifer Ann Watt

    Background Our systematic review examines the effectiveness and safety of non-pharmacologic and pharmacologic interventions in preventing or treating traumatic brain injury (TBI)-related delirium in acute care. Methods We searched four electronic databases (MEDLINE, EMBASE, CENTRAL/CDSR, and PsycINFO) to identify randomized controlled trials (RCTs), quasi-experimental, and observational studies. Eligible studies included adults with TBI, at least one comparator group, delirium as an outcome and took place in acute care. Two reviewers independently completed all study screening, data abstraction, and risk of bias assessment using the Cochrane risk of bias 2 tool for RCTs or risk of bias in non-randomized studies—of interventions tool for observational studies. We implemented the PROGRESS-Plus framework to describe social determinants of health (SDoH) reporting. Results We identified 20,022 citations, reviewed 301 in full text, and included eight studies in the descriptive synthesis. The mean age of study participants ranged from 32 to 62 years. 12.5% of included studies reported SDoH. Included studies had moderate-to-high risk of bias. Studies compared reorientation programs and an intervention bundle to usual care, but these interventions were not better than usual care in treating TBI-related delirium. Individual studies found that rosuvastatin and aripiprazole were more efficacious than placebo, and dexmedetomidine was more efficacious than propofol and haloperidol for preventing TBI-related delirium. No studies reported safety as the primary outcome. Conclusions We identified efficacious pharmacologic interventions for preventing TBI-related delirium, but these studies were at moderate-to-high risk of bias, which limits our confidence in these findings. Future studies should incorporate safety outcomes, and a diverse study population, including older adults.